The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...

NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent ...

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to chemotherapy, offering insight into why cancers recur. The study, published ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...